Baird lowered the firm’s price target on Intellia Therapeutics (NTLA) to $24 from $38 and keeps a Neutral rating on the shares. The firm said they are negative on the shares following an update from Alnylam (ALNY) of its ongoing HELIOS-B study which is a key bellwether of the ATTR-knock down space, and anticipate the update wil increase investor skepticism for Intellia’s NTLA-2001 program.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NTLA:
- Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
- Intellia Therapeutics initiated with a Peer Perform at Wolfe Research
- Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
- Cathie Wood’s ARK Investment bought 131K shares of Intellia Therapeutics today
- Intellia Therapeutics Reveals Positive Phase 1 Results
